Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 16/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481179 | 0.79 | ADRB1 (0.63) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL22481123 | 0.79 | ADRB1 (0.63) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL22490229 | 0.78 | SIGMAR1 (0.52) | SLC6A4 | |
| SCHEMBL26049444 | 0.77 | ADRB1 (0.51) | CYP2D6KCNH2 | |
| SCHEMBL27435772 | 0.76 | CASR (0.42) | CASRADRB2ADRB3MAPTTP53 | |
| SCHEMBL22490214 | 0.76 | ADAMTS4 (0.38) | CASRMAPTKCNH2 | |
| SCHEMBL22481125 | 0.76 | CASR (0.41) | CASRADRB2ADRB3MAPTFABP4 | |
| SCHEMBL5527612 | 0.74 | CASR (0.59) | CASR | |
| SCHEMBL22481150 | 0.70 | IDH1 (0.44) | — | |
| SCHEMBL29508554 | 0.70 | CASR (0.58) | CASRADRB2ADRB3CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225021-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | CURASEN THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
| WO-2020198466-A9 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020198466-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | CASR 675/4885ADRB2 1/4885ADRB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.